Daniel Jeffrey Moore Sells 1,500 Shares of LivaNova PLC (LIVN) Stock
LivaNova PLC (NASDAQ:LIVN) Director Daniel Jeffrey Moore sold 1,500 shares of the company’s stock in a transaction on Tuesday, January 15th. The stock was sold at an average price of $90.80, for a total transaction of $136,200.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Daniel Jeffrey Moore also recently made the following trade(s):
- On Saturday, December 15th, Daniel Jeffrey Moore sold 1,000 shares of LivaNova stock. The stock was sold at an average price of $91.85, for a total transaction of $91,850.00.
- On Thursday, November 15th, Daniel Jeffrey Moore sold 1,000 shares of LivaNova stock. The shares were sold at an average price of $116.68, for a total transaction of $116,680.00.
NASDAQ LIVN opened at $92.32 on Friday. LivaNova PLC has a 52-week low of $79.96 and a 52-week high of $131.54. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.65 and a quick ratio of 1.21. The stock has a market cap of $4.49 billion, a P/E ratio of 28.85, a P/E/G ratio of 2.68 and a beta of 0.91.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. PEAK6 Investments LLC purchased a new stake in LivaNova during the third quarter worth about $4,441,000. Invictus RG bought a new position in shares of LivaNova in the third quarter valued at approximately $283,000. Teachers Advisors LLC boosted its position in shares of LivaNova by 96.1% in the third quarter. Teachers Advisors LLC now owns 206,592 shares of the company’s stock valued at $25,611,000 after acquiring an additional 101,262 shares during the period. Dupont Capital Management Corp bought a new position in shares of LivaNova in the third quarter valued at approximately $719,000. Finally, Cibc Bank USA bought a new position in shares of LivaNova in the third quarter valued at approximately $227,000. Institutional investors and hedge funds own 86.89% of the company’s stock.
A number of equities analysts have issued reports on the stock. Jefferies Financial Group raised their price objective on shares of LivaNova to $150.00 and gave the company a “buy” rating in a research note on Tuesday, October 2nd. BTIG Research restated a “hold” rating on shares of LivaNova in a research note on Thursday, November 1st. BidaskClub raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a report on Thursday, November 8th. UBS Group started coverage on shares of LivaNova in a research report on Tuesday, November 27th. They issued a “neutral” rating and a $105.00 target price for the company. Finally, ValuEngine cut shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 28th. Four analysts have rated the stock with a hold rating and five have given a buy rating to the company. LivaNova presently has a consensus rating of “Buy” and an average price target of $122.20.
LivaNova Company Profile
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves.
Featured Article: Dividend Aristocrat Index
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.